These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 11594733)

  • 1. Interaction of new sulfaphenazole derivatives with human liver cytochrome p450 2Cs: structural determinants required for selective recognition by CYP 2C9 and for inhibition of human CYP 2Cs.
    Ha-Duong NT; Marques-Soares C; Dijols S; Sari MA; Dansette PM; Mansuy D
    Arch Biochem Biophys; 2001 Oct; 394(2):189-200. PubMed ID: 11594733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of sulfaphenazole derivatives and their use as inhibitors and tools for comparing the active sites of human liver cytochromes P450 of the 2C subfamily.
    Ha-Duong NT; Dijols S; Marques-Soares C; Minoletti C; Dansette PM; Mansuy D
    J Med Chem; 2001 Oct; 44(22):3622-31. PubMed ID: 11606127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: molecular origin of the specific inhibitory effects of sulfaphenazole on CYP 2C9 and consequences for the substrate binding site topology of CYP 2C9.
    Mancy A; Dijols S; Poli S; Guengerich P; Mansuy D
    Biochemistry; 1996 Dec; 35(50):16205-12. PubMed ID: 8973193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The substrate binding site of human liver cytochrome P450 2C9: an NMR study.
    Poli-Scaife S; Attias R; Dansette PM; Mansuy D
    Biochemistry; 1997 Oct; 36(42):12672-82. PubMed ID: 9335524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Substrate selectivity of human cytochrome P450 2C9: importance of residues 476, 365, and 114 in recognition of diclofenac and sulfaphenazole and in mechanism-based inactivation by tienilic acid.
    Melet A; Assrir N; Jean P; Pilar Lopez-Garcia M; Marques-Soares C; Jaouen M; Dansette PM; Sari MA; Mansuy D
    Arch Biochem Biophys; 2003 Jan; 409(1):80-91. PubMed ID: 12464247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sulfaphenazole derivatives as tools for comparing cytochrome P450 2C5 and human cytochromes P450 2Cs: identification of a new high affinity substrate common to those enzymes.
    Marques-Soares C; Dijols S; Macherey AC; Wester MR; Johnson EF; Dansette PM; Mansuy D
    Biochemistry; 2003 Jun; 42(21):6363-9. PubMed ID: 12767217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the substrate specificities of human liver cytochrome P450s 2C9 and 2C18: application to the design of a specific substrate of CYP 2C18.
    Minoletti C; Dijols S; Dansette PM; Mansuy D
    Biochemistry; 1999 Jun; 38(24):7828-36. PubMed ID: 10387023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs.
    Mancy A; Antignac M; Minoletti C; Dijols S; Mouries V; Duong NT; Battioni P; Dansette PM; Mansuy D
    Biochemistry; 1999 Oct; 38(43):14264-70. PubMed ID: 10572000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxidation of tienilic acid by human yeast-expressed cytochromes P-450 2C8, 2C9, 2C18 and 2C19. Evidence that this drug is a mechanism-based inhibitor specific for cytochrome P-450 2C9.
    Jean P; Lopez-Garcia P; Dansette P; Mansuy D; Goldstein JL
    Eur J Biochem; 1996 Nov; 241(3):797-804. PubMed ID: 8944768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytochrome P450 epoxygenases 2C8 and 2C9 are implicated in hypoxia-induced endothelial cell migration and angiogenesis.
    Michaelis UR; Fisslthaler B; Barbosa-Sicard E; Falck JR; Fleming I; Busse R
    J Cell Sci; 2005 Dec; 118(Pt 23):5489-98. PubMed ID: 16291720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease.
    Fichtlscherer S; Dimmeler S; Breuer S; Busse R; Zeiher AM; Fleming I
    Circulation; 2004 Jan; 109(2):178-83. PubMed ID: 14662709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19.
    Ha-Duong NT; Dijols S; Macherey AC; Goldstein JA; Dansette PM; Mansuy D
    Biochemistry; 2001 Oct; 40(40):12112-22. PubMed ID: 11580286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of amino acid substitutions that confer a high affinity for sulfaphenazole binding and a high catalytic efficiency for warfarin metabolism to P450 2C19.
    Jung F; Griffin KJ; Song W; Richardson TH; Yang M; Johnson EF
    Biochemistry; 1998 Nov; 37(46):16270-9. PubMed ID: 9819219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endothelium-derived hyperpolarizing factor synthase (Cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries.
    Fleming I; Michaelis UR; Bredenkötter D; Fisslthaler B; Dehghani F; Brandes RP; Busse R
    Circ Res; 2001 Jan; 88(1):44-51. PubMed ID: 11139472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro metabolism study of buprenorphine: evidence for new metabolic pathways.
    Picard N; Cresteil T; Djebli N; Marquet P
    Drug Metab Dispos; 2005 May; 33(5):689-95. PubMed ID: 15743975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of micellar electrokinetic capillary chromatography for evaluation of inhibitory effects on cytochrome P450 reaction.
    Konecný J; Micíková I; Remínek R; Glatz Z
    J Chromatogr A; 2008 May; 1189(1-2):274-7. PubMed ID: 18036599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling and synthesis of novel tight-binding inhibitors of cytochrome P450 2C9.
    Peng CC; Rushmore T; Crouch GJ; Jones JP
    Bioorg Med Chem; 2008 Apr; 16(7):4064-74. PubMed ID: 18255300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The inhibitory effect of tannic acid on cytochrome P450 enzymes and NADPH-CYP reductase in rat and human liver microsomes.
    Yao HT; Chang YW; Lan SJ; Yeh TK
    Food Chem Toxicol; 2008 Feb; 46(2):645-53. PubMed ID: 17950511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.
    Appiah-Opong R; de Esch I; Commandeur JN; Andarini M; Vermeulen NP
    Eur J Med Chem; 2008 Aug; 43(8):1621-31. PubMed ID: 18249473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.